Table 3.
Cytological diagnosis for screened women stratified by age
| Screened after invitation1 | Routine opportunistic testing2 | Sporadic opportunistic testing3 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n/N4 | % | n/N5 | % | PPD % (95 % CI)6 | PPR (95 % CI)7 | n/N8 | % | PPD % (95 % CI)9 | PPR (95 % CI)10 | |
| Cytological diagnosis | ||||||||||
| Normal cells | ||||||||||
| 23-28 | 92,693/104,448 | (88.7) | 32,034/36,357 | (88.1) | -0.6 (-1.0;-0.2) | 0.99 (0.98;1.00) | 9,141/10,417 | (87.8) | -0.6 (-1.6;-0.2) | 0.99 (0.98;1.00) |
| 29-34 | 87,023/93,912 | (92.7) | 33,615/36,896 | (91.1) | -1.6 (-2.0;-1.2) | 0.98 (0.98;1.00) | 11,887/13,004 | (91.4) | -1.3 (-1.8;-0.8) | 0.99 (0.98;1.00) |
| 35-42 | 149,489/158,989 | (94.0) | 40,764/44,098 | (92.4) | -1.6 (-1.9;-1.3) | 0.98 (0.98;0.99) | 16,960/18,280 | (92.8) | -1.2 (-1.6;-0.8) | 0.99 (0.98;0.99) |
| 43-49 | 149,650/157,444 | (95.0) | 30,384/32,427 | (93.7) | -1.3 (-1.6;-1.0) | 0.99 (0.98;0.99) | 15,878/16,889 | (94.0) | -1.0 (-1.4;-0.6) | 0.98 (0.99;1.00) |
| HSIL | ||||||||||
| 23-28 | 1,762/104,448 | (1.7) | 778/36,357 | (2.1) | 0.4 (-0.8;1.6) | 1.27 (1.17;1.38) | 156/10,417 | (1.5) | -0.2 (-2.2;1.8) | 0.89 (0.75;1.04) |
| 29-34 | 1,217/93,912 | (1.3) | 631/36,896 | (1.7) | 0.4 (-0.8;1.6) | 1.26 (1.15;1.39) | 105/13,004 | (0.8) | -0.5 (-0.2;1.3) | 0.59 (0.49;0.73) |
| 35-42 | 1,242/158,989 | (0.8) | 552/44,098 | (1.3) | 0.5 (-0.6;1.6) | 1.60 (1.45;1.77) | 89/18,280 | (0.5) | -0.3 (-1.8;1.2) | 0.62 (0.50;0.77) |
| 43-49 | 570/157,444 | (0.4) | 267/32,427 | (0.8) | 0.4 (-0.8;1.6) | 2.27 (1.97;2.63) | 58/16,889 | (0.3) | -0.1 (-1.6;1.4) | 0.95 (0.72;1.24) |
| Carcinoma in situ + AIS | ||||||||||
| 23-28 | 22/104,448 | (0.02) | 8/36,357 | (0.02) | 0.0 (-1.4;1.4) | 1.05 (0.47;2.35) | 2/10,417 | (0.02) | 0.0 (-2.0;2.0) | 0.91 (0.21;3.88) |
| 29-34 | 30/93,912 | (0.03) | 19/36,896 | (0.05) | 0.02 (-1.2;1.2) | 1.61 (0.91;2.86) | 5/13,004 | (0.04) | 0.01 (-1.8;1.9) | 1.20 (0.47;3.10) |
| 35-42 | 37/158,989 | (0.02) | 15/44,098 | (0.03) | 0.01 (-0.9;0.9) | 1.46 (0.80;2.66) | 6/18,280 | (0.03) | 0.01 (-1.4;1.4) | 1.41 (0.60;3.34) |
| 43-49 | 17/157,444 | (0.01) | 3/32,427 | (0.01) | 0.0 (-1.2;1.2) | 0.86 (0.25;2.92) | 1/16,889 | (0.01) | NA | 0.55 (0.07;4.12) |
| Carcinoma11 | ||||||||||
| 23-28 | 4/104,448 | (0.00) | 3/36,357 | (0.01) | 0.01 (-1.1;1.1) | 2.16 (0.48;9.63) | 1/10,417 | (0.01) | NA | 2.51 (0.28;22.4) |
| 29-34 | 9/93,912 | (0.01) | 6/36,896 | (0.02) | 0.01 (-1.2;1.3) | 1.70 (0.60;4.77) | 0/13,004 | (0.00) | NA | NA |
| 35-42 | 17/158,989 | (0.01) | 20/44,098 | (0.05) | 0.04 (-1.0;1.1) | 4.18 (2.19;7.99) | 0/18,280 | (0.00) | NA | NA |
| 43-49 | 12/157,444 | (0.01) | 13/32,427 | (0.04) | 0.03 (-1.2;1.3) | 5.26 (2.40;11.5) | 1/16,889 | (0.01) | NA | 0.78 (0.10;5.97) |
HSIL: high-grade squamous intraepithelial lesion, AIS: adenocarcinoma in situ, NA: Not available due to limited data
1) Cervical cytology obtained within 270 days after latest invitation.
2) Cervical cytology obtained between 271 days to 3 years after latest invitation or 2.5 to 3 years after latest cervical cytology.
3) Cervical cytology obtained less than 2.5 years after latest cervical cytology.
4) n: number of women with the cytological diagnosis within the age group, N:all women screened after invitation in the age group.
5) n: number of women with the cytological diagnosis within the age group, N:all women being routing opportunistic tested in the age group.
6) Prevalence proportion difference (%) for “routine opportunistic testing” compared to “screened after invitation”.
7) Prevalence proportion ratio for “routine opportunistic testing” compared to “screened after invitation”.
8) n: number of women with the cytological diagnosis within the age group, N:all women being sporadic opportunistic tested in the age group.
9) Prevalence proportion difference (%) for “sporadic opportunistic testing” compared to “screened after invitation”.
10) Prevalence proportion ratio for “sporadic opportunistic testing” compared to “screened after invitation”
11) Carcinoma including squamous and carcinoma adenocarcinoma.
Statically significant results are shown in bold